RT Journal Article
SR Electronic
T1 Impact of ‘EVEN FASTER’ concept to accelerate cervical cancer elimination in Norway: A model-based analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.06.23298170
DO 10.1101/2023.11.06.23298170
A1 Allison Portnoy
A1 Kine Pedersen
A1 Jane J. Kim
A1 Emily A. Burger
YR 2023
UL http://medrxiv.org/content/early/2023/11/07/2023.11.06.23298170.abstract
AB Background Experts have proposed an ‘EVEN FASTER’ concept targeting age-groups maintaining circulation of human papillomavirus (HPV). We explored the effects of these proposals compared with cervical cancer (CC) screening-based interventions on age-standardized incidence rate (ASR) and CC elimination (<4 cases per 100,000 women) timing in Norway.Methods We used a model-based approach to evaluate alternative HPV vaccination and CC screening scenarios compared with a status-quo scenario reflecting previous vaccination and screening. For cohorts ages 25–35 years, we examined 11 vaccination scenarios that incrementally increased vaccination coverage from current cohort-specific rates. Each vaccination scenario was coupled with three alternative screening strategies that varied the frequency of HPV-based screening. Population- and cohort-level outcomes included ASR, lifetime risk of CC, and colposcopy referrals.Results Several vaccination strategies coupled with de-intensified screening frequencies lowered population ASR, but did not accelerate CC elimination unless incremental vaccination coverage reached ∼90% for vaccine-naïve cohorts. Alternative strategies that increased screening adherence could both accelerate elimination and improve ASR compared to status-quo.Conclusions An ‘EVEN FASTER’ campaign is unlikely to accelerate CC elimination but may reduce population-level ASR. Alternatively, targeting under- and never-screeners may both eliminate CC faster and lead to greater health benefits compared with vaccination-based interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Norwegian Cancer Society [grant number 198073; PI: EAB]. The views expressed in this Article are those of the authors and do not necessarily represent the views of the Norwegian Cancer Society.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes